Free 24-hour delivery over £75 · Same-day dispatchOrder before 3pm - same-day dispatch · Free 24-hour delivery over £75
Research use only
Kovalabs supplies research-grade peptides to qualified researchers for laboratory use only. They are not medicines, are not for human or animal consumption, and are supplied with no dosing or medical guidance.
You must be 18 or over and a qualified person purchasing solely for scientific research.
Selecting ‘I agree’ confirms the above and your acceptance of our Research Disclaimer and Terms of Sale.
· 8 min read
KLOW looks like an acronym, and it is not one that decodes to its own ingredients. It is a market label for a grouping of four separate research peptides - KPV, GHK-Cu, BPC-157 and TB-500 - co-listed because their published studies sit in adjacent corners of the tissue-and-signalling literature, not because anyone has run them as a single thing. This is a research-context reference to what each of the four compounds actually is, with verified identifiers and bench handling. The compounds are supplied by Kovalabs strictly as separate research reagents for laboratory use; everything below describes what published studies have investigated, not any human use, and nothing here implies the four are combined, dosed or administered together. For the full position see our research disclaimer.
Honest answer: not much, etymologically. KLOW is a community blend name that vendors define slightly differently, and the letters do not map cleanly onto the four compounds the way an initialism would. The most useful way to read it is by its relationship to the older blend name GLOW. GLOW is the three-peptide grouping GHK-Cu, BPC-157 and TB-500; KLOW is that same trio with KPV added as a fourth. So KLOW is GLOW plus KPV, and the extra letter is the K of KPV. As supplied by Kovalabs, the KLOW grouping is offered either as one co-formulated 80mg vial or as four single-compound vials. Treat the name as a catalogue handle for four reagents, nothing more.
Each entry below is a separately verifiable chemical identity. The identifiers were cross-checked against PubChem; co-listing in this table groups the four by the molecular pharmacology their studies examine and implies no combined use, protocol or outcome.
| Compound | Identity / sequence | Molecular pharmacology grouping | Reference identifier |
|---|---|---|---|
| KPV | Lys-Pro-Val; C-terminal residues 11-13 of alpha-MSH | alpha-MSH-derived tripeptide; reported to lack the MC-receptor binding motif | PubChem CID 125672 |
| GHK-Cu | Copper(II) complex of glycyl-L-histidyl-L-lysine (Gly-His-Lys) | Copper-binding tripeptide coordination complex | PubChem CID 73587 (free GHK, L,L) |
| BPC-157 | 15-residue peptide H-GEPPPGKPADDAGLV-OH | Synthetic peptide derived from a gastric-juice protein fragment | PubChem CID 9941957 |
| TB-500 | Full-length thymosin beta-4 (TB-4), 43 residues, N-terminally acetylated | Actin-sequestering peptide (the complete thymosin beta-4 sequence) | PubChem CID 16132341 |
The grouping is worth taking apart, because the four sit in genuinely different mechanistic literatures. That distinctness is the whole point: these are four research questions, not one.
The C-terminal tripeptide of alpha-melanocyte-stimulating hormone (PubChem CID 125672, CAS 67727-97-3, C16H30N4O4). Its most-discussed feature is what it is missing: review literature notes KPV lacks the core His-Phe-Arg-Trp motif the melanocortin receptors require for high-affinity binding (PMID 21222263), so even its receptor route reads as unsettled. Studies have characterised it in NF-kappaB and MAPK signalling and in PepT1-transporter uptake using cell lines and animal models (PMID 18061177). Full identity work is on the KPV reference.
A copper(II) coordination complex of the tripeptide glycyl-L-histidyl-L-lysine (free GHK: PubChem CID 73587, CAS 49557-75-7, C14H24N6O4). The science here is coordination chemistry - how the Gly-His-Lys backbone binds a copper ion - and it carries a notorious database trap: a second PubChem record with the identical skeleton but unspecified stereochemistry, covered in full on the GHK-Cu reference. It is grouped here by its copper-binding pharmacology, not by any shared pathway with the other three.
A 15-residue synthetic peptide (H-GEPPPGKPADDAGLV-OH; PubChem CID 9941957, CAS 137525-51-0, C62H98N16O22) whose sequence corresponds to a fragment region of a protein found in gastric juice. The bulk of its literature is animal-model work, and there is no registered clinical trial - a point the BPC-157 reference does not soften.
At Kovalabs, yes. The TB-500 in KLOW is full-length synthetic thymosin beta-4 (TB-4): the complete 43-residue peptide (PubChem CID 16132341, CAS 77591-33-4, C212H350N56O78S, about 4,963 g/mol). Some suppliers use the TB-500 name for a seven-residue fragment instead, which is a different molecule. The distinction matters for anyone cross-referencing databases, and the TB-500 reference sets out which record is which.
Four. The word "stack" is a market label for a co-listed grouping, not a protocol, and Kovalabs offers KLOW either as one co-formulated 80mg lyophilised vial (GHK-Cu 50mg, BPC-157 10mg, TB-500 10mg, KPV 10mg) or as four separate single-compound vials. This matters beyond pedantry. You will see blends like this presented under a tissue-repair or recovery banner, with the implication that the grouping is itself a thing that does something. The literature does not support that leap: the four have distinct, separately studied mechanisms - a melanocortin-derived tripeptide, a copper-coordination complex, a gastric-protein-derived peptide and an actin-sequestering peptide - and no registered study has evaluated the combination as a unit. A shared shelf label is a marketing convenience, not evidence of a combined effect. Group the four by their molecular pharmacology, as above, and read any claim that the blend itself "works" as the claim it is.
The strongest claim here is the narrowest one: identity. All four compounds have unambiguous, cross-checked public-database identities - formula, mass, CID and CAS that agree - and that is exactly the part a certificate of analysis can verify in a vial. The mechanism work is real but scattered: each compound has its own in-vitro and animal literature (copper coordination, melanocortin-system and NF-kappaB signalling, actin regulation, assorted animal-model studies), the mechanisms are distinct rather than convergent, and none of it was measured in a human. The human evidence is weak twice over. Trial data for the individual compounds is thin to absent, and for the four together as a combination there is no registered clinical trial at all. None of the four is a licensed medicine, and the blend has not been shown to produce any defined outcome in humans.
The four are handled as four reagents, by the same general bench practice for lyophilised research peptides, anchored to peer-reviewed handling guidance (PMID 26719571). This is framed for laboratory use only and is not a preparation method for any use in humans or animals.
Storage: keep each dry, lyophilised powder desiccated and frozen (commonly -20 degrees C, and -20 to -80 degrees C for long-term archival), protected from moisture, and equilibrate a sealed vial to room temperature in a desiccator before opening so condensation does not settle onto the solid. Reconstitution as a bench procedure: add appropriate laboratory solvent slowly down the inner wall of each vial and swirl gently rather than shaking, then use each reconstituted solution within a defined working window for analysis and keep it refrigerated (2 to 8 degrees C) during that window. Where the compounds are supplied as separate vials, each is reconstituted, labelled and analysed on its own; our reconstitution guide covers the general method.
Purity and certificate of analysis: a vial that says one thing is not the same as a vial that is one thing, and a four-vial grouping multiplies the number of identities that have to be confirmed rather than assumed. Identity and quality are established analytically (PMID 26719571 covers peptide handling and quantification); Kovalabs batches are tested by ILS Laboratories for purity and net content by RP-HPLC and identity by HPLC retention time against a reference standard, and each batch carries its own lot-specific Certificate of Analysis, including the co-formulated KLOW vial (lot KLOW-337). Current documents are on our Certificates of Analysis page.
The KPV, GHK-Cu, BPC-157 and TB-500 supplied by Kovalabs are sold strictly as separate research chemicals for in-vitro and laboratory use by qualified researchers. They are not medicines, supplements, cosmetics or foods, and they are not for human or veterinary use, administration or consumption, individually or in any combination. Nothing on this page is medical, dosing or administration guidance, and no therapeutic, clinical or performance benefit is stated or implied for any compound or for the grouping. Under MHRA Guidance Note 8, a benefit claim would reclassify a research chemical as an unlicensed medicine; we make no such claim. Full terms are set out in our research disclaimer.
KLOW is an industry blend name for a grouping of four separate research peptides: KPV, GHK-Cu, BPC-157 and TB-500. Kovalabs supplies it either as one co-formulated 80mg vial or as four single-compound vials. Each is a research chemical, not a medicine.
KLOW is a community label rather than a strict acronym. The practical reading is that GLOW is the three-peptide grouping of GHK-Cu, BPC-157 and TB-500, and KLOW is that trio with KPV added as a fourth - KLOW is GLOW plus KPV. Vendors vary in exactly how they define both names.
Either. Kovalabs offers KLOW as one co-formulated 80mg lyophilised vial (GHK-Cu 50mg, BPC-157 10mg, TB-500 10mg, KPV 10mg) or as four single-compound vials. "Stack" here is a catalogue label for a co-listed grouping, not a protocol. Every batch, including the co-formulated vial, carries its own lot-specific Certificate of Analysis.
KPV: PubChem CID 125672 (Lys-Pro-Val). GHK-Cu: free GHK CID 73587 (glycyl-L-histidyl-L-lysine, copper-complexed). BPC-157: CID 9941957 (H-GEPPPGKPADDAGLV-OH). TB-500: CID 16132341 (full-length thymosin beta-4). Each is detailed on its own product reference.
No. All four compounds are supplied for research use only and are not for human or veterinary use, administration or consumption, alone or in combination. No medicinal, therapeutic or performance benefit is stated or implied, consistent with MHRA Guidance Note 8. See the research disclaimer for full terms.